News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
POLICY
China Waives Import Tariffs for Active Ingredients of Anti-cancer and Rare Disease Drugs in 2024
China will waive import tariffs for 62 active pharmaceutical ingredients (API) of anti-cancer drugs and 5 APIs of rare disease drugs, starting from Jan 1, 2024. Medical products such as nirmatrelvir for COVID-19, insulins for diabetes, vaccines, gene therapies, and more will also enjoy interim zero tariffs.
Jan 01, 2024
POLICY
China Levies Zero Tariff on Active Pharmaceutical Ingredients of COVID-19, Cancer, and Rare Disease Drugs
According to China's 2023 Tariff Adjustment Plan, tariffs are provisionally lowered to zero for 22 categories of active pharmaceutical ingredients of medicines for treating COVID-19, cancer, and rare diseases.
Jan 05, 2023
POLICY
China Emphasizes Rare Disease & Pediatric Drugs in Adjusting the 2022 National Reimbursement Drug List (NRDL)
On June 29, 2022, China NHSA issued the Work Plan for Adjusting the 2022 National Reimbursement Drug List (NRDL). NRDL is a list of drugs covered by the basic national insurance for healthcare, employment injury, and maternity.
Jul 04, 2022
POLICY
Law & Regulation
Marketing Approval
Volume-based Procurement
Health Insurance
Innovative Drug
Cancer
Cardiovascular Disease
Rare Disease
Drug Registration
New Drug
China's 2022 Two Sessions: Goals and Proposals for Pharma & Healthcare Industry
China's Government Work Report says one off the major tasks for 2022 is to improve medical and health services.
Mar 15, 2022
POLICY
China Adds 74 Drugs to National Reimbursement Drug List (NRDL)
On Dec. 3, China released its 2021 National Reimbursement Drug List (NRDL). NRDL is a list of drugs allowable for reimbursement by the national social health insurance fund under the social security system which has covered more than 1.36 billion people in China by the end of 2020.
Dec 08, 2021
POLICY
China to Exempt Import Tariffs on 61 Active Pharmaceutical Ingredients for Anticancer and Rare Disease Drugs
China will apply interim import tax rates that are lower than most-favored-nation tariffs on 883 kinds of goods from Jan. 1, 2021, according to the 2021 Tariff Adjustment Plan issued by the Customs Tariff Commission of the State Council on Dec. 23, 2020.
Mar 08, 2021
Most Popular
- Monthly Report: New Drug Approvals in China | February 2024
- Monthly Recap: China Pharmaceutical Regulatory Updates | February 2024
- 2023 China CDE Drug Evaluation Report
- [Updated] China Expedites Process for Transferring Overseas Drug Manufacturing Sites to China
- Monthly Report: New Drug Approvals in China | March 2024